Genmab — Februar 2017
-
Dette er egentlig et gammelt interview med Plesner, men helt genialt og med en del diskussion om anti PDL1 - apropos chatten tidligere. http://www.myelomacrowd.org/full-show-daratumumab-in-detail-for-multiple-myeloma-with-torben-plesner-md-vejle-hospital-denmark/
-
Eksempel: I actually have patients now who started out on the combination of daratmumab, lenalidomide and dexamethsone and are in stringent CR (complete response) and after two years they start complaining about side effects coming from lenalidomide and dexamenthasone, so I take them off of that and I just give them daratmumab and a little steroid
-
Interessante bud/udbud på skærmen her på fabrikken i Kvanløse.
-
Tak Bulder.
-
YES
-
øhhhh, det skal du ikke regne med, presser jo nok kursen lidt. Genmab sendte besked og kapitalforhøjelse for en times tid siden. medarbejder warrants til 103 millioner
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind